Eli Lilly's new oral GLP-1 medication orforglipron produced an average weight loss of 12.4% (27.3 pounds) in clinical trials.

Eli Lilly will significantly increase the price of its weight-loss drug Mounjaro in the United Kingdom in a bid to bring down ...

Trump’s push for price cuts and tariffs weighs on ‘obesity franchises’, which have missed out on equity market’s rise ...

Eli Lilly is one step closer to bringing an oral weight loss medicine to the booming obesity drug market. A clinical trial ...

Eli Lilly's obesity drugs delivered 38% revenue growth in the second quarter; but its oral GLP-1 candidate fell short, ...

The pricing of weight-loss and diabetes drugs like Lilly’s Zepbound and Mounjaro, and Novo’s Wegovy and Ozempic, is a ...

In a Phase 3 trial, drugmaker Eli Lilly and Company said it's oral GLP-1 pill showed similar results to injectable weight ...

In eagerly awaited results from a new study, the pharmaceutical company Eli Lilly reports that a pill its scientists ...

Eli Lilly (LLY) stock dips as the company reports Phase 3 trial results for its oral obesity drug orforglipron. Read more ...

Lilly has been a long-time backer of Superluminal, with the US big pharma company taking part in a $120m Series A round in ...

A legacy ranch in Jackson Hole, WY, has come onto the market, with records showing it is owned by former Eli Lilly exec Dr.

Eli Lilly will raise the UK list price of its weight-loss treatment Mounjaro by up to 170%, it said on Thursday, amid a White ...